Intermediate-term survival of robot-assisted versus open radical cystectomy for muscle-invasive and high-risk non-muscle invasive bladder cancer in The Netherlands

Autor: Hinsenveld, Florentien J., Boormans, Joost L, van der Poel, Henk G, van der Schoot, Deric K E, Vis, André N, Aben, Katja K H, Arends, TJ, Ausems, PJ, Baselmans, D, Berger, CPAM, Berrens, A, Bickerstaffe, H, Bos, SD, Braam, M, Buddingh, KT, Claus, S, Dekker, K, van Doeveren, T, Einerhand, SMH, Fossion, LMCL, van Gennep, EJ, van Ginkel, N, Palacios, LA Grondhuis, Hermans, TJN, Hobijn, MM, van Huystee, SH, Jaspers-Valentijn, M, Klaver, OS, Koldewijn, EL, Korsten, L, Lenting, A, Lentjes, KJ, Luiting, HB, van der Meer, S., Nieuwenhuijzen, JA, Noordzij, MA, Nooter, RI, Notenboom, CAW, Oomen, RJA, van Roermund, JGH, de Rooij, J, Roshani, H, Schrier, BP, van der Slot, MA, Somford, DM, Stelwagen, PJ, Stroux, AMA, van der West, A, Wijsman, BP, Windt, WAKM, van Zanten, P, van Beek, Sytse C

Publikováno v: In Urologic Oncology: Seminars and Original Investigations February 2022 40(2):60-60

Advancements in the front-line treatment of metastatic urothelial carcinoma.

Autor: Einerhand SMH; Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Antoni van Leeuwenhoek - Netherlands Cancer Institute, Amsterdam, The Netherlands. Electronic address: ms.vd.heijden@nki.nl.

Publikováno v: European urology focus [Eur Urol Focus] 2024 Aug 29. Date of Electronic Publication: 2024 Aug 29.

Prospective Evaluation of FDG-PET/CT for On-treatment Assessment of Response to Neoadjuvant or Induction Chemotherapy in Invasive Bladder Cancer.

Autor: Einerhand SMH; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Voskuilen CS; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., van de Putte EEF; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Donswijk ML; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Bruining A; Department of Radiology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., Mertens LS; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Hendricksen K; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands., Vegt E; Department of Nuclear Medicine, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands., van Rhijn BWG; Department of Urology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam, TheNetherlands.; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.

Publikováno v: Bladder cancer (Amsterdam, Netherlands) [Bladder Cancer] 2023 Mar 31; Vol. 9 (1), pp. 49-57. Date of Electronic Publication: 2023 Mar 31 (Print Publication: 2023).

Survival after neoadjuvant/induction combination immunotherapy vs combination platinum-based chemotherapy for locally advanced (Stage III) urothelial cancer.

Autor: Einerhand SMH; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dijk N; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Dorp J; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., de Feijter JM; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Montfoort ML; Department of Pathology, Netherlands Cancer Institute, Amsterdam, The Netherlands., van de Kamp MW; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., Schaake EE; Department of Radiation Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Boellaard TN; Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendricksen K; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands., van der Heijden MS; Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Molecular Carcinogenesis, Netherlands Cancer Institute, Amsterdam, The Netherlands., van Rhijn BWG; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany.

Publikováno v: International journal of cancer [Int J Cancer] 2022 Dec 01; Vol. 151 (11), pp. 2004-2011. Date of Electronic Publication: 2022 Jun 10.

Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer.

Autor: Einerhand SMH; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands., Black AJ; Vancouver Prostate Centre, Vancouver, Canada., Zargar H; Department of Urology, Western Health, Melbourne, Australia., Fairey AS; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA.; University of Alberta, Edmonton, AB, Canada., Dinney CP; Department of Urology, MD Anderson Cancer Center, Houston, TX, USA., Mir MC; Department of Urology, Fundacion Instituto Valenciano de Oncologia, Valencia, Spain., Krabbe LM; Department of Urology, University of Münster, Münster, Germany., Cookson MS; Department of Urology, University of Oklahoma College of Medicine, Oklahoma City, OK, USA., Jacobson NE; University of Alberta, Edmonton, AB, Canada., Montgomery JS; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Vasdev N; Hertfordshire and Bedfordshire Urological Cancer Centre, Department of Urology, Lister Hospital, Stevenage, UK.; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Yu EY; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Xylinas E; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA., Kassouf W; Department of Surgery (Division of Urology), McGill University Health Centre, Montreal, QC, Canada., Dall'Era MA; Department of Urology, David Medical Center, University of California at David, Sacramento, CA, USA., Sridhar SS; Princess Margaret Hospital, Toronto, ON, Canada., McGrath JS; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Aning J; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK.; Department of Surgery, Exeter Surgical Health Services Research Unit, Royal Devon and Exeter NHS Trust, Exeter, UK., Shariat SF; Department of Urology, Weill Cornell Medical College, Presbyterian Hospital New York, New York, NY, USA.; Department of Urology, Vienna General Hospital, Medical University of Vienna, Vienna, Austria., Wright JL; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Thorpe AC; Department of Urology, Freeman Hospital, Newcastle Upon Tyne, UK., Morgan TM; Department of Urology, University of Michigan Health System, Ann Arbor, MI, USA., Holzbeierlein JM; Department of Urology, University of Kansas Medical Center, Kansas City, KS, USA., Bivalacqua TJ; Division of Urology, University of Pennsylvania, Pennsylvania, PA, USA., North S; Cross Cancer Institute, Edmonton, AB, Canada., Barocas DA; Department of Urologic Surgery, Vanderbilt University Medical Center, Nashville, TN, USA., Lotan Y; Department of Urology, University of Texas Southern Medical Center, Dallas, TX, USA., Grivas P; Division of Oncology, Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Center, Seattle, WA, USA., Garcia JA; Department of Medicine, Case Comprehensive Cancer Center, Cleveland, USA., Stephenson AJ; Division of Urology, Rush University Medical Center, Chicago, IL, USA., Shah JB; Department of Urology, Stanford University School of Medicine, Stanford, CA, USA., Daneshmand S; USC/Norris Comprehensive Cancer Center, Institute of Urology, University of Southern California, Los Angeles, CA, USA., Zargar-Shoshtari K; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., Spiess PE; Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA., van Rhijn BWG; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands.; Department of Urology, Caritas St Josef Medical Center, University of Regensburg, Regensburg, Germany., Black PC; Vancouver Prostate Centre, Vancouver, Canada., Mertens LS; Department of Surgical Oncology (Urology), The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, The Netherlands. l.mertens@nki.nl.

Publikováno v: World journal of urology [World J Urol] 2022 Nov; Vol. 40 (11), pp. 2707-2715. Date of Electronic Publication: 2022 Sep 28.